Hebrew University of Jerusalem professor's research has led to the development of a product that has been shown in clinical trials to be successful in halting the growth of various cancer cells.
The research, conducted by Prof. Avraham Hochberg of the Silberman Institute of Life Sciences at the university, has won for him first prize among faculty members for this year's Kaye Innovations Awards, which was presented on June 9 during the annual Hebrew University Board of Governors meeting.
Common Diabetes Drug May 'Revolutionize' Cancer Treatment
Researchers have discovered that a widely used anti-diabetic drug can boost the immune system and increase the potency of vaccines and cancer treatments.
Researchers have discovered that a widely used anti-diabetic drug can boost the immune system and increase the potency of vaccines and cancer treatments.
Research has also demonstrated that the H19 gene plays a significant role in the tumor development process by enabling tumor cells to survive under stress conditions, such as low serum and low oxygen levels, that are typical conditions of the environment in which cancerous cells develop. This survival supports the growth of the tumor and the development of metastases.
The research and understanding of the origin of cancer and metastases has progressed significantly in recent years. In light of scientific breakthroughs in cancer research, and the role of the H19 gene in such processes, it is believed that an anti-cancer drug based on suppressing the expression of the H19 gene has the potential to provide benefits that are competitive with existing treatment methods.
Survival Time In Lung Cancer Treatment May Be Doubled By Inhibiting Nicotine Receptors
A team of Italian researchers have conducted experiments on mice and suggested that in lung cancer treatment, inhibiting nicotine receptors may help double survival time.
A team of Italian researchers have conducted experiments on mice and suggested that in lung cancer treatment, inhibiting nicotine receptors may help double survival time.
Source-Eurekalert
ARU
Cardiovascular Fitness Not Affected By Cancer Treatment
The cardiovascular fitness level of cancer survivors is not affected by many standard cancer therapies.
The cardiovascular fitness level of cancer survivors is not affected by many standard cancer therapies.
